Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma","authors":"James Fan Wu ,&nbsp;Idayat M. Akinola ,&nbsp;Anita D’Souza ,&nbsp;Rachel Cusatis","doi":"10.1016/j.clml.2025.07.002","DOIUrl":"10.1016/j.clml.2025.07.002","url":null,"abstract":"<div><h3>Purpose</h3><div>We investigated autologous stem cell transplantation (ASCT) barriers in a single-center qualitative study by interviewing patients with multiple myeloma (MM), transplant physicians (TPs), and referring physicians (RPs).</div></div><div><h3>Methods</h3><div>Patients with MM and referred for ASCT evaluation between January 01, 2021 and December 31, 2022, TPs from 2 Wisconsin transplant centers, and RPs from rural and urban Wisconsin were recruited. Interviews were conducted using a semi-structured interview guide focused on ASCT barriers. Transcripts were double-coded and reviewed. An initial codebook with prespecified themes based on the interview guide was developed and iteratively revised.</div></div><div><h3>Results</h3><div>Eighteen patients, 5 TPs, and 4 RPs were interviewed. Four major ASCT barriers themes were identified across all stakeholders: caregiver support, patient concerns and knowledge, financial toxicity, and logistics. Unique themes included social support by patients and ASCT referral by physicians. Lacking caregiver support was more common among single, childless, and socially/geographically isolated patients. Patients were most concerned about side effects, long hospital stays, and quality of life. Patients used online websites and support groups to gain knowledge and support. While most patients experienced financial toxicity, care costs were rarely discussed. Distance from transplant center, transportation, and care coordination were barriers. Referrals from community oncologists are a major barrier. Patients never seen at a transplant center may have the most barriers.</div></div><div><h3>Conclusion</h3><div>This qualitative study of both patients and physicians investigating barriers to access to ASCT in MM, provides a much-needed multistakeholder perspective. Interventional strategies targeting key barriers will be critical in improving ASCT utilization in MM.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages 26-33"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients","authors":"Irene Francés Alexandre ,&nbsp;Ana Gea Peña ,&nbsp;Ana Tobalina García ,&nbsp;Juan José Domínguez-García ,&nbsp;Elena Alejo Alonso ,&nbsp;Ana Pilar González-Rodríguez ,&nbsp;Irene Padilla ,&nbsp;Maialen Sirvent Auzmendi ,&nbsp;Ana Lobo Olmedo ,&nbsp;Ana María Vale López ,&nbsp;Irene Castaño Caballero ,&nbsp;Evelyn Valencia ,&nbsp;Paula Melero Valentín ,&nbsp;Ianire Etxeguren Urkixo ,&nbsp;María de las Mercedes Luque Romero ,&nbsp;Javier Larreina Pérez ,&nbsp;Borja Puertas Martínez ,&nbsp;Fernando Escalante Barrigón ,&nbsp;María Oviedo Madrid ,&nbsp;Julia Bannatyne Undabeitia ,&nbsp;Enrique María Ocio","doi":"10.1016/j.clml.2025.08.018","DOIUrl":"10.1016/j.clml.2025.08.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Autologous stem cell transplantation (ASCT) with melphalan 200 mg/m² remains a standard treatment for multiple myeloma (MM). We analyzed the incidence and risk factors associated with the development of mucositis in 1,268 MM patients who underwent ASCT between 2017 and 2022 across 13 national centers.</div></div><div><h3>Results</h3><div>Median age was 60 years (24-77), and 44% were female. Induction therapy included chemotherapy or cyclophosphamide (principally VCD) in 32%, and 21% had creatinine &gt; 1 mg/dL. Melphalan was administered in a single day (Mel1) in 52% and over 2 days (Mel2) in 48%. Prophylaxis measures included cryotherapy (75%), G-CSF (78%) and antibiotics (37%). Mucositis occurred in 84% of patients, with 26% experiencing severe cases (WHO grade III-IV), which were significantly associated with increased intravenous opioids use, parenteral nutrition, and febrile episodes. Severe mucositis was more common in women (32% vs. 22%), patients over 60 (53% vs. 60%), chemotherapy induction (37% vs. 20%), creatinine &gt; 1 mg/dL (34% vs. 24%), those not receiving G-CSF (35% vs. 24%) or antibiotic (36% vs. 16%). It was also more common with single day melphalan (29% vs. 24%). In the multivariable analysis, all factors except chemotherapy-based induction were identified as independent predictors of severe mucositis.</div></div><div><h3>Conclusion</h3><div>In our population, an increased incidence of severe mucositis was observed in nonmodifiable factors such as sex and renal function. However, the implementation of modifiable factors, including the use of prophylactic G-CSF or antibiotics and administering melphalan over 2 days could diminish the severity of this complication.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e50-e56"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association and Prognostic Significance of Comorbidities in Individuals With MGUS","authors":"Sawyer Bawek ,&nbsp;Nour Nassour ,&nbsp;Malak Alharbi ,&nbsp;Alan Hutson ,&nbsp;Sarah Parker ,&nbsp;Joseph D. Tario ,&nbsp;Hamza Hassan ,&nbsp;Scott I. Abrams ,&nbsp;Philip L. McCarthy ,&nbsp;Jens Hillengass ,&nbsp;Janine M. Joseph","doi":"10.1016/j.clml.2025.08.019","DOIUrl":"10.1016/j.clml.2025.08.019","url":null,"abstract":"<div><h3>Introduction</h3><div>Monoclonal gammopathy of undetermined significance (MGUS) is a benign precursor of multiple myeloma, but little is known about the role of comorbidities in progression.</div></div><div><h3>Materials and Methods</h3><div>A retrospective review of medical records of patients with MGUS (n = 150) or a negative MGUS workup (n = 96) seen at a comprehensive cancer center between 2007 and 2023 was performed. Charlson Comorbidity Index (CCI) scores, descriptive characteristics, and overall (OS) and progression-free (PFS) survival were abstracted. Group differences (MGUS vs negative) in CCI and other characteristics were tested with Student’s t-tests and Pearson’s chi-square tests. Univariate and multivariate Cox proportional hazard models were used to model the association between CCI and OS and PFS in patients with MGUS.</div></div><div><h3>Results</h3><div>Patients with MGUS had a higher mean CCI (<em>P</em> = .01) and prevalence of diabetes mellitus with end-organ damage (P &lt; .05) and solid tumors (<em>P</em> = .01) than patients with a negative MGUS workup. Each additional CCI point was associated with shorter OS (HR 1.50, <em>P</em>&lt; .01) and PFS (HR 1.25, <em>P</em> &lt; .01). Results were not confounded by age, body mass index, or sex.</div></div><div><h3>Conclusions</h3><div>Our study suggests that comorbidities are relevant to risk of MGUS and that prevention and management of comorbidities in patients with MGUS is indicated and may be associated with improved outcomes.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e57-e61.e2"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A SEER Analysis","authors":"Shivani Modi ,&nbsp;Srinishant Rajarajan ,&nbsp;Hardik Jain ,&nbsp;Claudia Dourado","doi":"10.1016/j.clml.2025.07.012","DOIUrl":"10.1016/j.clml.2025.07.012","url":null,"abstract":"<div><h3>Survival Outcomes</h3><div>Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia. CLL treatment has evolved dramatically from alkylator-based regimens to chemoimmunotherapy and targeted therapies. This study evaluated real-world survival outcomes across treatment eras using population-based data, focusing on patients who received active systemic therapy to assess treatment effectiveness rather than natural disease progression.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using surveillance, epidemiology, and end results (SEER) data from 1995 to 2020, restricting analysis to CLL patients who received active systemic treatment. Patients were stratified into three treatment eras based on treatment initiation date: Pre-novel therapy era (1995-2004, alkylator-based regimens), Early novel therapy era (2005-2014, chemoimmunotherapy with anti-CD20 monoclonal antibodies), and modern novel therapy era (2015-2020, targeted therapies including BTK inhibitors and BCL-2 inhibitors). Era boundaries accounted for the lag between regulatory approval and community adoption. Overall survival was calculated from treatment initiation date, with era assignment based on first-line therapy to maintain temporal consistency.</div></div><div><h3>Results</h3><div>Among 49,056 CLL patients across three treatment eras, median overall survival improved significantly from 3.5 years (95% CI, 3.2-3.8) in the pre-novel therapy era (1995-2004) to 5.2 years (95% CI, 4.9-5.6) in the early novel therapy era (2005-2014), and 7.8 years (95% CI, 6.9-8.7) in the modern novel therapy era (2015-2020). Multivariable Cox regression analysis demonstrated progressive reductions in mortality risk, with adjusted hazard ratios of 0.75 (95% CI, 0.68-0.82, <em>P</em> &lt; .001) for the Early Novel era and 0.45 (95% CI, 0.38-0.53, <em>P</em> &lt; .001) for the Modern era compared to the Pre-Novel era. Complete response rates increased from 15% to20% in the Pre-Novel era to over 60% in the Modern era with targeted therapies.</div></div><div><h3>Conclusions</h3><div>This analysis demonstrates significant improvements in survival outcomes for CLL patients across treatment eras, with the most pronounced benefits observed in the modern targeted therapy era. By focusing on treated patients and calculating survival from treatment initiation, we isolated the impact of therapeutic advances from disease biology and patient selection factors. However, the COVID-19 pandemic's disproportionate impact on immunocompromised CLL patients, particularly affecting the modern therapy era, represents an important limitation that may underestimate the true survival benefits of contemporary targeted therapies. These findings support the continued development and adoption of novel therapeutic strategies in CLL management.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages 42-48"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm","authors":"Fadi G. Haddad,&nbsp;Jennifer Croden,&nbsp;Koji Sasaki,&nbsp;Ghayas C. Issa,&nbsp;Naveen Pemmaraju,&nbsp;Hagop Kantarjian,&nbsp;Elias Jabbour","doi":"10.1016/j.clml.2025.07.017","DOIUrl":"10.1016/j.clml.2025.07.017","url":null,"abstract":"<div><div>Philadelphia chromosome-positive chronic myeloid leukemia (CML) during pregnancy is rare, with an annual incidence of 1 per 100,000 pregnancies. Managing CML in pregnancy is challenging due to concerns about the teratogenicity of the BCR::ABL1 tyrosine kinase inhibitors (TKIs). While some pregnant patients with chronic-phase CML may be managed with close monitoring and no therapy, others, particularly those diagnosed in the first trimester, may require treatment to prevent disease progression and maternal complications. Imatinib has been associated with an increased risk of congenital malformations when used in the first trimester; however, growing evidence support its safety later in the second and third trimesters. Similar to imatinib, nilotinib has limited placental transfer with no congenital malformations reported to date in women who received it later in pregnancy. Dasatinib, however, is contraindicated due to its high association with congenital abnormalities and hydrops fetalis. Ponatinib exposure has been linked to a higher incidence of Hirschsprung’s disease and should be avoided in pregnancy. Although no congenital malformations have been reported with bosutinib or asciminib, data remains limited, and their use is not recommended. Interferon-α is a safer alternative during pregnancy but is slower in achieving cytoreduction, and less effective compared to TKIs. Hydroxyurea, while not teratogenic, may increase the risk of miscarriage and low birth weight. If a male patient is receiving TKI therapy, the female partner can safely become pregnant without an increased risk for the fetus. Shared decision-making and thorough counseling on the risks and benefits of different treatment options are essential. This review examines the potential fetotoxicity of CML therapies, focusing on TKIs and alternative treatments for pregnant women.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages 19-25"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies","authors":"Ryan Storgard ,&nbsp;Rachel E. Reingold ,&nbsp;Rose Parisi ,&nbsp;Stephen W. Dusza ,&nbsp;Sarah J. Noor ,&nbsp;Jae H. Park ,&nbsp;Craig S. Sauter ,&nbsp;Kevin J. Curran ,&nbsp;M. Lia Palomba ,&nbsp;Gunjan Shah ,&nbsp;Roni Shouval ,&nbsp;Miguel-Angel Perales ,&nbsp;Michael Scordo ,&nbsp;Alina Markova","doi":"10.1016/j.clml.2025.09.012","DOIUrl":"10.1016/j.clml.2025.09.012","url":null,"abstract":"<div><h3>Background</h3><div>CD19 CAR T-cell therapy is a significant advance in B-NHL and ALL. This study describes the incidence, onset, and factors of dermatologic adverse events (dAE) post-therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis at Memorial Sloan Kettering Cancer Center (4/2013-8/2020) identified 193 patients undergoing CD19 CAR T-cell therapy. We aimed to characterize dAEs post CAR T-cell therapy including the 100-day cumulative incidence, time to dAE onset, and associations with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).</div></div><div><h3>Results</h3><div>Eighty-two patients experienced 94 dAEs within the first 100 days (incidence: 0.42 (95% CI: 0.36-0.51) post CAR T-cell therapy. Common dAEs were rash (30.9%, <em>n</em> = 29) including maculopapular rash, inflammatory papules, and local erythema; infection (23.4%, <em>n</em> = 22) including cellulitis and folliculitis; and xerosis (16.0%, <em>n</em> = 15). Specific early onset dAEs included rash and chemotherapy-related events, eg, alopecia, mucositis (median 12- and 17-days postinfusion, respectively). Thrombocytopenic purpura and xerosis presented later (median 22-and 25-days). CRS and dAEs occurred in 33.5% of patients, with CRS preceding dAEs in 86% of cases. Among 15% with ICANS and dAEs, ICANS was antecedent in 67%.</div></div><div><h3>Conclusion</h3><div>dAEs following CAR T-cell therapy are common but mostly low-grade and often manifest within the initial month postinfusion.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e120-e126"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis","authors":"Moazzam Shahzad ,&nbsp;Muhammad Kashif Amin ,&nbsp;Sohaib Irfan ,&nbsp;Rania Ahsan ,&nbsp;Hana Qasim ,&nbsp;Muhammad Jawad Javed ,&nbsp;Matthew McGuirk ,&nbsp;Sibgha Gull Chaudhary ,&nbsp;Iqra Anwar ,&nbsp;Abdulraheem Yacoub ,&nbsp;Anurag K. Singh ,&nbsp;Mehdi Hamadani ,&nbsp;Joseph P. Mcguirk ,&nbsp;Muhammad Umair Mushtaq","doi":"10.1016/j.clml.2025.08.012","DOIUrl":"10.1016/j.clml.2025.08.012","url":null,"abstract":"<div><h3>Background</h3><div>Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only curative option for myelofibrosis (MF) but is often underutilized in patients aged ≥ 65 due to concerns about treatment-related toxicity.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of chronic-phase MF allo-HCT recipients using the publicly available CIBMTR P-5640 dataset (2008-2019). Key endpoints included overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-vs-host disease (GVHD)-related outcomes. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox regression models. Statistical analysis was performed using R (v4.3.2), with statistical significance defined as <em>P</em> &lt; .05.</div></div><div><h3>Results</h3><div>We included 856 MF allo-HCT recipients (aged ≥ 65: n = 259, aged &lt; 65: n = 597). The 2-year OS, DFS, and GVHD-free, relapse-free survival (GRFS) for patients ≥ 65 years were 62%, 33%, and 12%, respectively. Rates of relapse, NRM, grade II–IV acute GVHD, and chronic GVHD were 43%, 27%, 46%, and 42%, respectively. In multivariable analysis, age ≥ 65 years was independently associated with inferior DFS (HR 1.26, 95% CI 1.03-1.55, <em>P</em> = .025); however, there was no impact on other post-transplant outcomes. Independent predictors of worse outcomes in older patients included splenic radiation and ATG use, secondary MF, higher comorbidities (HCT-CI ≥ 3), mismatched donor type, and bone marrow graft.</div></div><div><h3>Conclusions</h3><div>In myelofibrosis patients aged 65 years and above undergoing allogeneic HCT, a favorable 2-year overall survival of 62% was noted with an inferior DFS compared to younger patients, while other post-transplant outcomes remained comparable. These findings support allo-HCT as a viable option in selected elderly MF patients using tailored transplant strategies.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e32-e40"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score–Adjusted Cohort Study","authors":"Moath Albliwi ,&nbsp;Emily C. Zabor ,&nbsp;John Hanna ,&nbsp;Jessica El-Asmar ,&nbsp;Daniel P. Nurse ,&nbsp;Ameed Bawwab ,&nbsp;Hasan Abuamsha ,&nbsp;Yomna Abu-Farsakh ,&nbsp;Asad Rauf ,&nbsp;Heya Batah ,&nbsp;Ahmed Mohamed ,&nbsp;Muaz Alsabbagh Alchirazi ,&nbsp;Akriti G. Jain ,&nbsp;John C Molina ,&nbsp;Sophia Balderman ,&nbsp;Abhay Singh ,&nbsp;Aaron T. Gerds ,&nbsp;Sudipto Mukherjee ,&nbsp;Ronald M. Sobecks ,&nbsp;Betty Hamilton ,&nbsp;Moaath K. Mustafa Ali","doi":"10.1016/j.clml.2025.08.016","DOIUrl":"10.1016/j.clml.2025.08.016","url":null,"abstract":"<div><h3>Background</h3><div>Venetoclax (VEN) combined with hypomethylating agents (HMA) is established as standard of care for elderly or unfit patients with newly diagnosed acute myeloid leukemia (AML). While emerging evidence supports its use in fit, younger patients, data on its comparative efficacy versus intensive chemotherapy (IC) remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study to compare composite complete response (CCR), overall survival (OS), and event-free survival (EFS) in patients with AML who received 7 + 3 IC vs. HMA+VEN. All AML patients aged 60–75 years treated between 1/2015 and 9/2023 were included. Propensity score (PS) adjustment and multivariable regression were used to adjust outcomes.</div></div><div><h3>Results</h3><div>The study included 172 patients who received 7 + 3 and 74 who received HMA+VEN. After adjustment, the average age was –68 years in both groups. The CCR was significantly lower with HMA+VEN (51.4%) than with 7 + 3 (66.9%; <em>P</em> = .025), but this was not significant in the weighted logistic regression model (OR: 0.65, 95% CI: 0.32-1.32, <em>P =</em> .2). PS-adjusted median OS was 18.0 months for 7 + 3 vs. 9.5 months for HMA+VEN (<em>P =</em> .14). VEN+HMA was associated with similar PS-adjusted median EFS (7.2 vs. 7 months, <em>P =</em> .91) compared to 7 + 3. Allogeneic transplant was not different between 7 + 3 and HMA+VEN (48% vs. 24%, log-rank <em>P =</em> .6).</div></div><div><h3>Conclusions</h3><div>In AML patients aged 60–75 years, HMA + VEN achieved CCR, OS, and EFS comparable to those of the 7 + 3 regimen, consistent with previous reports. However, our analysis may be underpowered or confounded, and a sufficiently powered randomized trial is needed to definitively assess the efficacy, toxicity, and cost-effectiveness of HMA + VEN vs. 7 + 3.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e41-e49"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Multicolor Flow Cytometry Method for Multiple Myeloma","authors":"Noa Ofir ,&nbsp;Ety Rozenberg ,&nbsp;Omri Sharabi ,&nbsp;Miri Zektser ,&nbsp;Ory Rouvio ,&nbsp;Roi Gazit","doi":"10.1016/j.clml.2025.09.014","DOIUrl":"10.1016/j.clml.2025.09.014","url":null,"abstract":"<div><h3>Background</h3><div>Multiple myeloma (MM) is a bone marrow plasma cells malignancy. Despite impressive advancements of treatments, MM remains incurable due to complex clonality. Here, we present a novel 14-color flow cytometry (FACS) protocol for robust detection and visualization of MM clonality.</div></div><div><h3>Method</h3><div>We developed a single-tube 14-color FACS protocol to analyze fresh bone marrow samples, tested on 8 MM patients. A premixed, stable antibody cocktail was used to enhance reproducibility and streamline workflow. Dimensionality reduction technique (t-SNE) was applied to visualize plasma cell clonality.</div></div><div><h3>Results</h3><div>Our panel shown CD38⁺ CD138⁺ plasma cells, and their clonality. As expected, MM patients had unique clonal patterns with significant heterogeneity at primary diagnosis. Advanced t-SNE analysis provides a convenient visualization of multi-parameter heterogeneity in a unified 2-D plot. Importantly, our data presents some similarities among patients, and further differences between primary analysis and secondary relapse.</div></div><div><h3>Conclusions</h3><div>Taken together, our protocol provides a robust and efficient method for improving MM diagnosis using commercially available antibodies and a standard FACS machine. Concise visualization of multi-parameter FACS will help therapeutic decisions and advance the personalized treatment strategies with emerging antigen-specific drugs.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"26 1","pages":"Pages e132-e140.e5"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit.","authors":"Cesar Rodriguez, Cyrille Touzeau, Edvan de Queiroz Crusoe, Fernando Vieira Pericole, Vania Hungria","doi":"10.1016/j.clml.2025.12.015","DOIUrl":"https://doi.org/10.1016/j.clml.2025.12.015","url":null,"abstract":"<p><strong>Purpose: </strong>Bispecific antibodies emerged as a new class of treatment for patients with relapsed/refractory multiple myeloma. Education on the practicalities of delivery and patient management is vital to optimize outcomes with these novel agents.</p><p><strong>Methods: </strong>A group of 5 experienced hematologists from centers in the United States, Europe and Latin America met to discuss key considerations for bispecific antibody therapy and agree on best practice advice.</p><p><strong>Results and discussion: </strong>This paper presents advice for best practice at each stage of the bispecific antibody therapy patient journey: patient eligibility, pretreatment medication, step-up dosing, treatment, management of adverse events and long-term care.</p><p><strong>Conclusion: </strong>We believe that the expert insights presented here will help to educate healthcare professionals and optimize patient outcomes by guiding the implementation of bispecific antibody therapy into real-world practice.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}